Bristol-Myers Squibb (NYSE: BMY), with headquarters in New York City, is a global leader in the research and development of innovative treatments for cancer, cardiovascular and metabolic diseases, hepatitis, HIV/AIDS, psychiatric disorders, rheumatoid arthritis, and other serious diseases. Our key business is Biopharmaceuticals, with 2010 sales of US$19.5 billion and R&D investment of US$3.6 billion.
Bristol-Myers Squibb (Taiwan) Ltd., the Taiwan subsidiary, was set up by Bristol-Myers in August 1965, predating the 1989 merger with Squibb that established what at the time was the world’s second largest pharmaceutical company. Starting in 2002, logistics operations in Taiwan have been outsourced to a professional logistics company to enable us to focus on providing clients with the best possible service. In addition, service centers have been set up in Taichung and Kaohsiung to better serve the central and southern Taiwan markets.
At Bristol-Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are committed to pursue excellence, reliability, growth, innovation, and fairness. We also believe deeply in corporate social responsibility. These values have enabled us to maintain our leading role in the market and to increase annual return for our shareholders.